File(s) under permanent embargo
Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile
journal contribution
posted on 2023-06-08, 17:16 authored by Steven Knapper, Timothy ChevassutTimothy Chevassut, Rafael Duarte, Juan Miguel Bergua, Olga Salamero, Malin Johansen, Tove Flem Jacobsen, Petter-Arnt Hals, Wenche Rasch, Athos Gianella-Borradorif, Matthew SmithElacytarabine is the elaidic acid ester derivative of cytarabine, designed to enter cells independently of nucleoside transporters. Effects of elacytarabine on QT interval, serum lipid profile and clinical activity were investigated in 43 relapsed/refractory AML patients. Mean maximum increase in corrected QT interval of 24( ± 29)ms occurred 48 h after elacytarabine infusion without associated arrhythmias or clinical symptoms. A non-clinically significant, elacytarabine exposure-dependent increase in cholesterol was caused by a cholesterol rich lipoprotein depleted of apolipoprotein B formed by infused phospholipids complexing cholesterol. Elacytarabine is clinically active in relapsed/refractory AML: overall response rate (CR + CRi) was 44% (16/36 with 7 non-evaluable patients) and adverse events were manageable.
History
Publication status
- Published
File Version
- Published version
Journal
Leukemia ResearchISSN
0145-2126Publisher
ElsevierExternal DOI
Issue
3Volume
38Page range
346-351Department affiliated with
- Clinical and Experimental Medicine Publications
Research groups affiliated with
- Haematology Research Group Publications
Full text available
- No
Peer reviewed?
- Yes